Showing results (151-160 of 280) with videos related to

Sort By:
Pageof 28
Cancer Chemotherapy and Pharmacology|March 13, 2014
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancerIslam R Younis, Daniel J George, Terence J McManus, et al.
Biosensors & Bioelectronics|May 12, 2020
Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical applicationJiyoon Bu, Ashita Nair, Luke J Kubiatowicz, et al.
Clinical Genitourinary Cancer|April 2, 2014
A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinomaRhonda L Bitting, Patrick Healy, Patricia A Creel, et al.
The Prostate|September 10, 2019
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancerDaniel J George, Susan Halabi, Patrick Healy, et al.
MDM Policy & Practice|November 12, 2025
Treatment Preferences among Patients with Hormone-Sensitive Prostate Cancer in France, Spain, China, South Korea, and Japan: A Discrete-Choice ExperimentJuan Marcos Gonzalez, Arijit Ganguli, Alicia K Morgans, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 22, 2014
Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?Suzanne B Stewart, Judd W Moul, Thomas J Polascik, et al.
BMC Cancer|August 8, 2021
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinomaThomas Powles, Toni K Choueiri, Robert J Motzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2014
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigenMaha Hussain, Paul G Corn, M Dror Michaelson, et al.
JAMA Oncology|March 7, 2024
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate CancerDaniel E Spratt, Daniel J George, Neal D Shore, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2003
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT modelPradip K Majumder, Jen Jen Yeh, Daniel J George, et al.
Pageof 28